<DOC>
	<DOCNO>NCT02456038</DOCNO>
	<brief_summary>The aim study assess safety efficacy Asfotase Alfa ( ALXN1215 ) patient hypophosphatasia</brief_summary>
	<brief_title>Safety Efficacy Asfotase Alfa Patients With Hypophosphatasia ( HPP )</brief_title>
	<detailed_description />
	<mesh_term>Hypophosphatasia</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Patients must meet one selection criterion follow `` 1 '' , `` 2 '' , `` 3 '' , must meet selection criterion `` 4 . '' 1 . Patient already treat Asfotae Alfa ( ALXN1215 ) clinical trial 2 . Patient diagnose HPP 3 . Documented diagnosis HPP indicate : 1 . Total serum alkaline phosphatase lower limit normal age 2 . Ultrasonographic feature prenatal , characterize : 1 ) severe short extremity ( femur length &lt; 4SD second third trimester ) 2 ) extend metaphysis ( femur metaphysis length femur length &gt; 0.33 ) 3 ) craniotabes 4 ) Hypoplastic thorax ( Thoracic abdominal circumference &lt; 0.6 ) ( 3 ) Computed tomographic finding prenatal , characterize : 1 . Generalized decreased ossification 2 . Extreme shorten tubular bone 3 . Hypoplastic thorax ( 4 ) Radiographic evidence HPP , characterize : 1 ) Flared frayed metaphyses 2 ) Severe , generalize osteopenia 3 ) Widened growth plate 4 ) Areas radiolucency sclerosis ( 5 ) Two follow HPPrelated finding : 1 . History presence : Nontraumatic postnatal fracture Delayed fracture heal 2 . Nephrocalcinosis history elevate serum calcium 3 . Functional craniosynostosis 4 . Respiratory compromise rachitic chest deformity 5 . Vitamin B6 dependent seizures 6 . Failure thrive 7 . Premature tooth loss ( 6 ) Patient mutation tissue nonspecific ALP gene 4 . Parent legal guardian ( ) must provide write informed consent prior study procedure perform must willing comply studyrequired procedure 1 . Current evidence treatable form rickets 2 . Serum calcium phosphate level normal range 3 . Pregnant woman nurse mother 4 . Patient enforce suitable contraceptive measure clinical trial 5 . Prior treatment bisphosphonates 6 . Treatment investigational drug within 1 month prior start asfotase alfa treatment 7 . Current enrollment study involve investigational new drug , device treatment HPP ( e.g. , bone marrow transplantation ) 8 . Clinically significant disease precludes study participation , opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>